Excellent outcome with reduced treatment for infants with disseminated neuroblastoma without MYCN gene amplification.
about
Treatment including anthracyclines versus treatment not including anthracyclines for childhood cancerTreatment including anthracyclines versus treatment not including anthracyclines for childhood cancerOutcome after reduced chemotherapy for intermediate-risk neuroblastomaPlasma levels of soluble HLA-E and HLA-F at diagnosis may predict overall survival of neuroblastoma patientsPEA15 impairs cell migration and correlates with clinical features predicting good prognosis in neuroblastomaGlycobiology of neuroblastoma: impact on tumor behavior, prognosis, and therapeutic strategies.Criteria for evaluation of disease extent by (123)I-metaiodobenzylguanidine scans in neuroblastoma: a report for the International Neuroblastoma Risk Group (INRG) Task Force.Outcomes for children and adolescents with cancer: challenges for the twenty-first century.Predicting outcomes for children with neuroblastoma using a multigene-expression signature: a retrospective SIOPEN/COG/GPOH study.Racial and ethnic disparities in risk and survival in children with neuroblastoma: a Children's Oncology Group study.A PCNA-derived cell permeable peptide selectively inhibits neuroblastoma cell growth.Prognostic value of the stage 4S metastatic pattern and tumor biology in patients with metastatic neuroblastoma diagnosed between birth and 18 months of age.Expression of miR-487b and miR-410 encoded by 14q32.31 locus is a prognostic marker in neuroblastoma.Segmental chromosomal alterations lead to a higher risk of relapse in infants with MYCN-non-amplified localised unresectable/disseminated neuroblastoma (a SIOPEN collaborative study).Disparities in cancer outcomes: lessons learned from children with cancerAdvances in Risk Classification and Treatment Strategies for Neuroblastoma.Serum-Based Quantification of MYCN Gene Amplification in Young Patients with Neuroblastoma: Potential Utility as a Surrogate Biomarker for Neuroblastoma.Prognostic value of ferritin, neuron-specific enolase, lactate dehydrogenase, and urinary and plasmatic catecholamine metabolites in children with neuroblastomaDFMO/eflornithine inhibits migration and invasion downstream of MYCN and involves p27Kip1 activity in neuroblastoma.Molecular characterization and classification of neuroblastoma.p53 family: Therapeutic targets in neuroblastoma.Neuroblastoma: the impact of biology and cooperation leading to personalized treatments.Ten challenges in the management of neuroblastoma.Emerging drugs for neuroblastoma.Retrospective study of neuroblastoma in Chinese neonates from 1994 to 2011: an evaluation of diagnosis, treatments, and prognosis : a 10-year restrospective study of neonatal neuroblastoma.At the frontier of progress for paediatric oncology: the neuroblastoma paradigm.Does aggressive surgical resection improve survival in advanced stage 3 and 4 neuroblastoma? A systematic review and meta-analysis.New immunotherapeutic strategies for the treatment of neuroblastoma.Revisions to the International Neuroblastoma Response Criteria: A Consensus Statement From the National Cancer Institute Clinical Trials Planning Meeting.Metastatic neuroblastoma in infants: are survival rates excellent only within the stringent framework of clinical trials?Factors associated with recurrence and survival length following relapse in patients with neuroblastoma.Residual tumor in cases of intermediate-risk neuroblastoma did not influence the prognosis.Reply: Comment on 'Beta-blockers increase response to chemotherapy via direct anti-tumour and anti-angiogenic mechanisms in neuroblastoma'--β-blockers are potent anti-angiogenic and chemo-sensitising agents, rather than cytotoxic drugs.Molecular Classification Substitutes for the Prognostic Variables Stage, Age, and MYCN Status in Neuroblastoma Risk Assessment.Do you believe in miracles?Image-defined risk factor assessment of neurogenic tumors after neoadjuvant chemotherapy is useful for predicting intra-operative risk factors and the completeness of resection.Neuroblastoma: clinical and biological approach to risk stratification and treatment.Bilateral adrenal neuroblastoma in the infant: Is it an image-defined risk factor?Primary orbital neuroblastoma in a 1-month-old boy.Age-dependent accumulation of genomic aberrations and deregulation of cell cycle and telomerase genes in metastatic neuroblastoma.
P2860
Q24193790-F6920BE6-EEAE-412E-A186-37754AD4D227Q24234833-51DF836B-B4C5-4432-9264-F35406295025Q24633964-BD8D9E60-EE50-4A2C-872B-C247B10B07E0Q28304289-B7626E35-84E1-46AB-9333-83E75FB7C66FQ30417536-0766E158-0348-4339-AB62-F89DF56CD531Q33659849-59763E31-0C01-4F65-BCCE-6D8FAAF2844EQ33834340-2411A3B8-B12B-4DFC-A999-45056AFD918FQ33897659-5C902232-6897-417A-9635-D198BB4619AEQ34606771-8DB45471-563E-4EE9-B77D-62DF6747BD9FQ34662881-7EE5F73A-0A17-4EFB-AC73-73C8B8161BB6Q35146771-B270AA12-4B2D-43F1-853D-7201C78548C4Q35565637-9829A0BB-A5EE-48BF-B252-F715D51FBA59Q35620669-091909CA-56FD-4E3B-A499-58F7BC0E4AC4Q35653969-022CDA7D-6025-4534-BBD1-CD29804573A7Q36015045-4EAD4381-1369-4464-9FA1-7BDF816D1EBFQ36053801-1B3BF4C1-3A9E-4887-BFC6-3129FF2E18D0Q36101495-4A2477AD-1E80-4A3E-8AF1-20333082DB99Q36446812-6C819530-B081-4641-96B2-C31BFDA7657EQ36755665-9485E131-C5E0-4FBD-B384-45BE0CD02B8CQ37515355-8D26407B-8173-4048-A8AF-CB4E34318528Q37707387-4E688073-EAFB-4C29-AAFB-EA608A47C675Q38014527-E1400DF8-B6B8-46F9-896F-806C260AA44EQ38029366-E8144E25-C264-40F2-8167-1A027D7E516BQ38108399-747070E1-A0E0-4530-B862-AA5962594DADQ38159931-E24623C6-BD33-4849-B6A4-04C1C56F855EQ38161274-19253EA0-6989-4D26-B438-6C37BCD85D30Q38253390-C2C9D8C9-7E8F-49AC-A063-ED6F06E6CF82Q38389316-FBAC816A-CD81-48A8-AF3A-3EA963BAA05CQ38804821-28929F92-2D29-424B-A57D-85A664E65D23Q39866458-87210DD9-7E10-4EE3-B4A5-CEBE62CCFA58Q40518791-A7209115-80D4-4756-AAA3-A11E2A9DBF8DQ40743437-2248E1C2-61A0-4EC9-ABE9-4227B818AA2EQ42957826-382D85FD-3114-4D98-8279-1CF6A4CEA305Q47133240-22E2C802-41B3-43CA-8A90-6E0B45A4AE3DQ48085771-2E1E6931-8779-4404-9EAF-064CB15AB38BQ49126642-16F1A4AF-9FBA-42D1-A65D-DC3A329A4907Q52639269-D9373830-ACF2-4EC6-B69D-0E68BEB24493Q52982411-F0158B69-F0BA-49B7-BB0E-1C649D84B8E0Q53078825-F8FBCF4E-7966-4D3A-9561-AA116262C86EQ53193095-3D7AECC4-C399-4CBE-943A-513D17FCF3C2
P2860
Excellent outcome with reduced treatment for infants with disseminated neuroblastoma without MYCN gene amplification.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Excellent outcome with reduced ...... thout MYCN gene amplification.
@en
Excellent outcome with reduced ...... thout MYCN gene amplification.
@nl
type
label
Excellent outcome with reduced ...... thout MYCN gene amplification.
@en
Excellent outcome with reduced ...... thout MYCN gene amplification.
@nl
prefLabel
Excellent outcome with reduced ...... thout MYCN gene amplification.
@en
Excellent outcome with reduced ...... thout MYCN gene amplification.
@nl
P2093
P50
P356
P1476
Excellent outcome with reduced ...... thout MYCN gene amplification.
@en
P2093
Ana Forjaz de Lacerda
Andrea Di Cataldo
Andrew D J Pearson
Benédicte Brichard
Bruno De Bernardi
Caroline Ellershaw
Caroline Munzer
Ellen Ruud
Hervé Rubie
Jean Michon
P304
P356
10.1200/JCO.2008.17.5877
P407
P577
2009-01-26T00:00:00Z